Determinants of survival in HER2+ metastatic esophagogastric cancer.
This cohort contains serial WES alterations from patient samples collected as part of NCT02954536, a phase 2 evaluation of chemotherapy with trastuzumab and pembrolizumab in advanced/unresectable or metastatic esophagogastric cancer.